Zebra Capital Management’s Myriad Genetics MYGN Stock Holding History

Zebra Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-13,672	Closed	-$261K	–	77
2022 Q3	$261K	Sell	13,672 -1,680	-11%	-$38.6K	0.99%	43
2022 Q2	$279K	Buy	15,352 +1,361	+10%	+$28.3K	0.82%	48
2022 Q1	$353K	Sell	13,991 -218	-2%	-$5.58K	0.81%	39
2021 Q4	$392K	Sell	14,209 -5,239	-27%	-$152K	0.63%	55
2021 Q3	$628K	Sell	19,448 -10,389	-35%	-$345K	0.76%	38
2021 Q2	$912K	Sell	29,837 -3,223	-10%	-$93.1K	1.07%	28
2021 Q1	$1.01M	Buy	+33,060	New	+$938K	1.11%	24
2018 Q4	–	Sell	-4,361	Closed	-$201K	–	413
2018 Q3	$201K	Buy	+4,361	New	+$194K	0.09%	383
2018 Q2	–	Sell	-12,248	Closed	-$362K	–	353
2018 Q1	$362K	Buy	12,248 +3,886	+46%	+$131K	0.13%	270
2017 Q4	$287K	Sell	8,362 -1,673	-17%	-$56.4K	0.1%	287
2017 Q3	$363K	Buy	10,035 +995	+11%	+$28.4K	0.12%	229
2017 Q2	$234K	Buy	+9,040	New	+$192K	0.07%	244

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Zebra Capital Management's MYGN Position: Q4 2022 in Review

Zebra Capital Management sold out of Myriad Genetics (MYGN) in Q4 2022, closing a stake of 13,672 shares — an estimated $261K sold.

Zebra Capital Management first reported a position in MYGN in Q2 2017 and held it in 12 quarters. The position peaked at $1.01M in Q1 2021. 197 funds tracked by Wall St. Rank hold MYGN as of Q4 2022.

Zebra Capital Management reported no remaining Myriad Genetics position as of Q4 2022 after selling out during the quarter.
Zebra Capital Management sold 13,672 Myriad Genetics shares in Q4 2022, an estimated $261K.
Zebra Capital Management first reported a position in Myriad Genetics in Q2 2017 and held it in 12 quarters.
Zebra Capital Management's Myriad Genetics position peaked at $1.01M in Q1 2021.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2022.

Based on Zebra Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.